Abstract:Background: Ischemic stroke is one of the leading causes of mortality and disability. The neuroimaging methods are the gold standard for diagnostics. Biomarkers of cerebral ischemia are considered to be potentially helpful in the determination of the etiology and prognosis of patients with ischemic stroke. Aim: This study aimed to investigate the usefulness of serum S100B protein levels as a short- and long-term prognostic factor in patients with ischemic stroke. Study design and methods: The study group comprised 65 patients with ischemic stroke. S100B protein levels were measured by immunoenzymatic assay. Short-term functional outcome was determined by the NIHSS score on day 1 and the difference in the NIHSS scores between day 1 and day 9 (delta NIHSS). Long-term outcome was assessed by the modified Rankin Scale (MRS) at 3 months after the stroke. At the end of the study, patients were divided into groups based on the NIHSS score on day 9 (0–8 "good" and >8 "poor"), the delta NIHSS ("no improvement" ≤0 and >0 "improvement"), and the MRS ("good" 0–2 and >2 "poor"). Differences in S100B levels between groups were analyzed with the ROC curve to establish the optimal cut-off point for S100B. The odds ratio was calculated to determine the strength of association. Correlations between S100B levels at three time points and these variables were evaluated. Results: We revealed a statistically significant correlation between S100B levels at each measurement point (<24 h, 24–48 H, 48–72 h) and the NIHSS score on day 9 (R Spearman 0.534, 0.631, and 0.517, respectively) and the MRS score after 3 months (R Spearman 0.620, 0.657, and 0.617, respectively). No statistically significant correlation was found between S100B levels and the delta NIHSS. Analysis of the ROC curve confirmed a high sensitivity and specificity for S100B. The calculated AUC for the NIHSS on day 9 were 90.2%, 95.0%, and 82.2%, respectively, and for the MRS, 83.5%, 83.4%, and 84.0%, respectively. After determining the S100B cut-off, the odds ratio for beneficial effect (NIHSS ≤ 8 at day 9 or MRS 0–2 after 3 months) was determined for each sampling point. Conclusion: S100B is a useful marker for predicting short- and long-term functional outcomes in patients with ischemic stroke.

Application significance of S100B in the assessment of blood-brain barrier injury

High S100B Levels in Cerebrospinal Fluid and Peripheral Blood of Patients with Acute Basal Ganglial Hemorrhage Are Associated with Poor Outcome.

Expression of S100B Protein Levels in Serum and Cerebrospinal Fluid with Different Forms of Neuropsychiatric Systemic Lupus Erythematosus.

A biosensor for S100B detection based on PSS-MA-GoldMag-LFIA in early clinical diagnosis of brain damage

Clinical Evaluation of Prognosis of Severe Posttraumatic Brain Injuries by Using S-100B

Serum S100 Protein and Cerebral Injury After Cardiac Surgery

Umbilical Artery Blood S100β Protein: a Tool for the Early Identification of Neonatal Hypoxic-Ischemic Encephalopathy

Relationship between cerebrospinal fluidα-Synuclein and prognosis of patients with traumatic brain injury

Clinical Significance of Neuron Specific Enolase and S100 Beta Protein in Intracranial Infection and Brain Injury.

Diagnostic and prognostic value of serum S100B in sepsis-associated encephalopathy: A systematic review and meta-analysis

Correlation of serum S100B protein and human anti-brain tissue antibody levels with cognitive function in patients with Alzheimer's disease

The predictive value of S-100B and NSE in outcome of patients with severe head injury

Effect of Non-Cerebral Trauma on the Value of Serum S100B

Change of Concentrations of Serum Cyclophilin A in Patients with Traumatic Brain Injury and its Clinical Significance

Serum S-100B adds incremental value for the prediction of symptomatic intracranial hemorrhage and brain edema after acute ischemic stroke

Role of S-100B,NSE and MBP in Prediction of Prognosis in Patients with Severe Head Injury

The study of serum levels of anti-brain antibody and plasma levels of S100b protein in schizophrenic

Predicting Short- and Long-Term Functional Outcomes Based on Serum S100B Protein Levels in Patients with Ischemic Stroke

The association between serum S100β levels and prognosis in acute stroke patients after intravenous thrombolysis: a multicenter prospective cohort study

Correlation between the expression of β2-microglobulin and S100 calcium binding protein B in cerebrospinal fluid and the occurrence of communicating hydrocephalus after traumatic brain injury

Influence of Blood–Brain Barrier Integrity on Brain Protein Biomarker Clearance in Severe Traumatic Brain Injury: A Longitudinal Prospective Study